Testing for PIK3CA mutation, germline BRCA1/2, PALB2 pathologic variant, homologous recombination deficiency (HRD), PD-L1 expression, and TMB is some of the latest developments to guide breast cancer treatment. The gene discussed is PALB2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.